ArticlePloS one2016
How Can Viral Dynamics Models Inform Endpoint Measures in Clinical Trials of Therapies for Acute Viral Infections?
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Enhancing viral dynamics modeling: reliable initial estimation and validity conditions for quasi-steady state approximation (QSSA).BMC biology · 2025Article
- Astodrimer Sodium Nasal Spray versus Placebo in Non-Hospitalised Patients with COVID-19: A Randomised, Double-Blinded, Placebo-Controlled Trial.Pharmaceutics · 2024Article
- Public Health Impact of Paxlovid as Treatment for COVID-19, United States.Emerging infectious diseases · 2024Article
- Article
- Unexpected Cytomegalovirus (CMV) Replication Kinetics in CMV Donor-Seropositive, Recipient-Seronegative Liver Transplant Recipients Receiving Preemptive Antiviral Therapy.The Journal of infectious diseases · 2022Article
- Article
- Comparing antiviral strategies against COVID-19 via multiscale within-host modelling.Royal Society open science · 2021Article
- Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial.EClinicalMedicine · 2021Article
- Article
- Adenovirus Viral Kinetics and Mortality in Ex Vivo T Cell-Depleted Hematopoietic Cell Transplant Recipients With Adenovirus Infection From a Single Center.The Journal of infectious diseases · 2020Article
- A theoretical framework for transitioning from patient-level to population-scale epidemiological dynamics: influenza A as a case study.Journal of the Royal Society, Interface · 2020Article
- Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials.CPT: pharmacometrics & systems pharmacology · 2020Review
- Mathematical modelling identifies the role of adaptive immunity as a key controller of respiratory syncytial virus in cotton rats.Journal of the Royal Society, Interface · 2019Article
- Association between adenovirus viral load and mortality in pediatric allo-HCT recipients: the multinational AdVance study.Bone marrow transplantation · 2019Article
- Diagnostic Parameters of Adenoviremia in Pediatric Stem Cell Transplant Recipients.Frontiers in microbiology · 2019Article
- High-resolution epidemic simulation using within-host infection and contact data.BMC public health · 2018Article
- The Mechanisms for Within-Host Influenza Virus Control Affect Model-Based Assessment and Prediction of Antiviral Treatment.Viruses · 2017Article
- Inhibition of Brazilian ZIKV strain replication in primary human placental chorionic cells and cervical cells treated with nitazoxanide.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute viral infections pose many practical challenges for the accurate assessment of the impact of novel therapies on viral growth and decay. Using the example of influenza A, we illustrate how the measurement of infection-related quantities that determine the dynamics of viral load within the human host, can inform investigators on the course and severity of infection and the efficacy of a novel treatment. We estimated the values of key infection-related quantities that determine the course of natural infection from viral load data, using Markov Chain Monte Carlo methods. The data were placebo group viral load measurements collected during volunteer challenge studies, conducted by Roche, as part of the oseltamivir trials. We calculated the values of the quantities for each patient and the correlations between the quantities, symptom severity and body temperature. The greatest variation among individuals occurred in the viral load peak and area under the viral load curve. Total symptom severity correlated positively with the basic reproductive number. The most sensitive endpoint for therapeutic trials with the goal to cure patients is the duration of infection. We suggest laboratory experiments to obtain more precise estimates of virological quantities that can supplement clinical endpoint measurements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.